Healthcare, Pharma &amp; Life Sciences

Healthcare, Pharma & Life Sciences Draft Consultation

Healthcare regulatory insight

Prescription-medicine advertising: proposed restrictions extend the compliance discussion across distribution

The Ministry’s draft-policy announcement brings retail, wholesale and distribution licence holders into the proposed prior-sanction framework for Schedule H, H1 and X advertising. Businesses should review communication controls without treating the draft as enacted law.

Industry, model and participation details

Healthcare, Pharma & Life Sciences Digital, Telecom & Electronics Manufacturing, MSME & Industrial Policy Ministry of Health and Family Welfare · Institution named in the cited development

Draft amendment · consultation linked to public Gazette availability

11 October 2026BP-20261011-11

Healthcare, Pharma & Life Sciences Dated participation record · Innovation funding applications

Policy and industry intelligence

PRIP innovation funding: early discovery, development and commercialisation routes

The second call introduces a New Discovery route for startup and MSME drug-innovation portfolios.

Industry, model and participation details

Healthcare, Pharma & Life Sciences Financial Services, Capital Markets & Insurance Department of Pharmaceuticals · Responsible institution

PRIP second call · Innovation funding applications: Dated participation record · checked 4 October 2026

Institutional cooperation

4 October 2026BP-20261001-10

Healthcare, Pharma & Life Sciences

Policy and ecosystem insight

NHA’s digital-health launches: governed data and claims infrastructure become a business priority

The new provider-registry, secure-data and claims tools create implementation questions for hospitals, payers and health-technology businesses. The opportunity lies in interoperability, evidence quality, workflow integration and accountable use of data.

Industry, model and participation details

Healthcare, Pharma & Life Sciences AI, Cybersecurity & Data Governance Digital, Telecom & Electronics Financial Services, Capital Markets & Insurance National Health Authority · Institution named in source record NHA · Institution named in source record IISc Bengaluru · Institution named in source record

Tools and frameworks launched · institution-level implementation

28 September 2026BP-20260927-10

Financial Services, Capital Markets & Insurance

Executive insight

GST reform: protect cash flow by fixing the operating interpretation

For large enterprises, rate changes, exemptions and process reform become material through credit treatment, contracts, master data and the quality of the compliance record.

Industry, model and participation details

Financial Services, Capital Markets & Insurance Manufacturing, MSME & Industrial Policy Healthcare, Pharma & Life Sciences Digital, Telecom & Electronics Governance & Admin GST Council · Institution named in source record CBIC · Institution named in source record Ministry of Finance · Institution named in source record Department of Financial Services · Institution named in source record GSTN · Institution named in source record

Effective framework · further process-reform watch

17 September 2026

Explore sector intelligence →

Bharat Pulse · TLGS Research

Research for this sector

Asset development, implementation milestones and policy context for industry.

Procurement conditions are governed by the issuing authority’s notice and amendments.

Policy update

Biopharma SHAKTI: translate the Budget programme into concrete projects

Budget programme · implementation watch₹10,000 crore · five-year programme

Union Budget 2026–27 announced Biopharma SHAKTI with an outlay of ₹10,000 crore over five years.

Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Education & Skills

Bharat Pulse brief

CDSCO September enforcement notice: compliance systems matter

Regulatory notice

CDSCO’s public-notice list carries a 5 September 2026 item on coordinated action against illegal manufacture and distribution of misbranded drugs.

Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Governance & Admin

Bharat Pulse brief

CDSCO pendency publications: distinguish reporting month from upload date

Regulatory operations update

CDSCO’s register includes August 2026 pendency statements uploaded in early September, including a West Zone publication dated 8 September.

Healthcare, Pharma & Life Sciences · Manufacturing, MSME & Industrial Policy · Governance & Admin

Trade & treaties

UK–India CETA: preference planning after entry into force

In force · product-specific conditions apply

UK guidance published on 4 September 2026 records that CETA entered into force on 15 July 2026. It also sets India’s graduation from the UK’s DCTS for 15 July 2028.

Trade, Customs & Strategic Supply Chains · Manufacturing, MSME & Industrial Policy · Healthcare, Pharma & Life Sciences · Agriculture, Food Processing & Rural Economy · Financial Services, Capital Markets & Insurance

Trade & treaties

EFTA–India TEPA: an investment and technology-partnership lens

In force · investment objectives not guarantees

EFTA records TEPA entering into force on 1 October 2025. The participating EFTA states are Iceland, Liechtenstein, Norway and Switzerland. Its investment-mobilisation objectives are long-term goals, not automatic funding entitlements.

Trade, Customs & Strategic Supply Chains · Manufacturing, MSME & Industrial Policy · Financial Services, Capital Markets & Insurance · Healthcare, Pharma & Life Sciences · Power, Energy & Renewables

Trade & treaties

EU–India FTA: concluded negotiations are not the same as entry into force

Negotiations concluded · implementation status to verify

The European Commission’s agreements page records conclusion of EU–India FTA negotiations on 27 January 2026. That statement alone does not establish entry into force.

All work in this sector →

Our work · Institutional client

Tata 1mg — a pan-India regulatory engagement

TLGS is a long-standing pan-India regulatory advisory and operational-compliance partner to Tata 1mg, supporting defined assignments across retail pharmacy, e-pharmacy, institutional healthcare and e-diagnostics.

Explore the engagement →

Sector experience · TLGS Our Work

From sector knowledge to practical action.

Digital health & technology-enabled wellbeing

Digital health: institutional market access & growth architecture

Strategic advisory connecting a digital-health enterprise’s consumer, corporate and institutional channels with partnership design, governance and regulatory positioning.

Market-development & institutional structuringChallenge, solution & delivery →

From expertise to engagement

TLGS services for this sector

Explore all relevant services →

E2 · Policy & Regulatory Advisory

Regulatory Advisory Withdrawal & Policy Correction

Structured legal and technical representations where an advisory, notification or administrative position creates material policy inconsistency.

E5 · Policy & Regulatory Advisory

PSU Healthcare & Aggregator Compliance Strategy

Regulatory and data-governance advisory for healthcare aggregators and technology platforms working with public-sector institutions.

F1 · Digital Infrastructure, AI & Cyber Governance

AI Governance & Regulatory Compliance

Governance and regulatory-readiness advisory for AI models, enterprise applications and data-dependent businesses.

F3 · Digital Infrastructure, AI & Cyber Governance

Digital Public Goods & API Infrastructure Strategy

Strategic advisory on interoperable digital platforms and public-infrastructure models for India-facing and cross-border initiatives.

F4 · Digital Infrastructure, AI & Cyber Governance

Cyber Compliance & Incident-Readiness

Governance-led preparation for cyber-compliance requirements and incident-response readiness.

H1 · Licensing, Permits & National Compliance

Pan-India Licensing & Operational Compliance

Coordinated operational-compliance support for multi-location pharmacy, diagnostics, retail, warehousing and related regulated operations.

TLGS expertise

Our people in this sector

Meet our people →

Shri P. Udayakumar

Former CMD, NSIC & NSIC Venture Capital Fund

Regional President — Chennai / South India

Chair, South India Enterprise Desk

Former CMD and board-level leader of NSIC and NSIC Venture Capital Fund, bringing MSME, enterprise-development and growth-finance experience.

Ms. Somya Satsangi

Former Senior Director, Tata Consultancy ServicesIndependent-director and Risk Management Committee chair experience, Dr Lal PathLabs

Director & Practice Chair

Corporate Governance, Risk, Digital Strategy & Board Advisory

Board and strategy professional with experience in corporate governance, risk oversight, technology commercialisation and healthcare.

Mr. Philippe Gerwill

Corporate technology and transformation experience at Novartis, Lonza and Ciba

Principal Advisor

Digital Health, AI & Healthcare Innovation

View profile LinkedIn profile

Digital-health futurist and strategic advisor with more than three decades of experience across pharmaceutical, biotechnology and specialty-chemicals businesses. His work connects responsible AI, enterprise transformation, healthcare innovation and international partnerships.

Shri Rajesh P. Chaudhari

Former Assistant Commissioner, Food and Drugs Administration, Maharashtra State

Regional Principal Advisor

Pharmaceutical Regulatory Affairs, Licensing & Compliance (Maharashtra)

Former Assistant Commissioner, FDA Maharashtra, with more than three decades of experience in pharmaceutical regulation, licensing, inspections, quality systems and regulatory administration.

Shri Amogh Bansal

Regional Lead

UAE & Middle East Business Operations

Consulting and business-analysis professional with experience in healthcare initiatives, MSME policy, technology and cross-border coordination.